obesity drug news today glp-1 october 21 2025 New Daily Weight Loss Pill Aims to Take on Ozempic Chart: 1 in 8 Americans

In the SURMOUNT-1 trial, adults with obesity (without diabetes) receiving the highest dose (15 mg weekly) achieved an average weight loss of 20.9% over 72 weeks, compared to 3.1% with placebo

Alpha Arbutin Supports a refined and uniform complexion while minimizing the appearance of dark spots and discolorations

In addition, clustering analysis of GPX genes showed that GPX2, 3, 5, 6 , and 8 demonstrate relatively similar expression profiles compared to those of GPX1, 4 , and 7

Wolf E, Hoeflich A, Lahm H

Although it is naturally produced by the body, many people have resorted to oral supplements and taking it intravenously, which has raised legitimate health issues, Dr Rajamanya added